Scientists are increasingly paying attention to human milk oligosaccharides (HMOs) As one of them, para-lacto-N-hexaose (pLNH) shows some potential activities. As a trusted operator, CD BioGlyco provides you with advanced services for pLNH production.
HMOs are essential components in human milk. They can act as bait and disrupt the binding of virus lectins or microorganisms with host cell receptors, thus preventing these organisms from infecting the host. Due to the variety and complexity of HMOs, many excellent potential effects on the human body remain to be explored. The natural advantages of HMO make the imitation of infant formula with its composition ratio the first choice for non-breastfed infants. As one of the HMOs, pLNH was first isolated and characterized by Yamashita et al. from human milk in 1977. The core portion of this oligosaccharide is a linear hexasaccharides.
In recent years, a powder mixture is expected to be used in the food market. Its main ingredient is Lacto-N-tetraose, which also contains a small amount of pLNH and other sugars. The product is fermented by two kinds of Escherichia coli(optional degradation strain and production strain). Experts have made a comprehensive assessment of its safety, and information provided regarding the manufacturing process, specifications, and composition do not raise safety concerns. This novel product is expected to be added to various foods, including infant and young food, food supplements, and foods for special medical purposes and it may benefit the general population.
Di-fucosylated and tri-fucosylated derivatives of pLNH are similar to the carbohydrate part of cell surface glycolipids and glycoproteins, which appear in the cell membrane of transformed cells. They are tumor-associated antigens in healthy donors, which exist in a small amount in the human milk of healthy donors, and this provides direction and convenience for related biological research.
Fig.1 Structures of α1, 2-fucosylated HMO-type glycan related to pLNH. (Fang, et al. 2018)
CD BioGlyco has accumulated a variety of Solutions for pLNH production to meet changing client needs, including but not limited to the following technologies:
Selection and identification of suitable enzymes.
Optimal enzyme expression levels.
Develop and optimize glycosylation routes.
CD BioGlyco is committed to using our expertise for pLNH production to promote continuous innovation. If you are interested in our services, please contact us feel free.
Reference
